Noted This Week

AbbVie announced that it will buy ImmunoGen in a deal worth about $10.1 billion, acquiring ImmunoGen’s mirvetuximab soravtansine (Elahere), a first-in-class antibody–drug conjugate (ADC) approved for the treatment of platinum-resistant ovarian cancer. Mirvetuximab soravtansine binds to folate receptor alpha (FRα), delivering the microtubule-disrupting agent DM4 to cancer cells. ImmunoGen has other ADCs in its pipeline, including IMGN151, a next-generation anti-FRα ADC for ovarian cancer that could potentially treat other tumor types, and pivekimab sunirine, an anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer.

More Noted This Week, November 17–30   »